Topical Androgen Receptor Inhibitors Market Size & Share, by Indication (Androgenetic Alopecia, Hirsutism); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5828
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Topical Androgen Receptor Inhibitors Market size is anticipated to reach USD 221.8 Million by the end of 2036, growing at a CAGR of 14% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of topical androgen receptor inhibitors was USD 40 Million. The need for potent topical androgen receptor inhibitors is driven by the increasing incidence of androgenetic alopecia and hirsutism, two disorders associated with androgen receptors. AGA is becoming more commonplace worldwide because of a combination of lifestyle, hormone fluctuations, and genetics. A greater number of patients are seeking effective treatments, such as topical androgen receptor inhibitors, as a result of this rising incidence. Excessive hair growth in women, frequently with a male pattern, is a symptom of hirsutism. Hormonal imbalances and conditions such as polycystic ovarian syndrome (PCOS) can aggravate hirsutism. Data from the World Health Organization (WHO) in June 2023 indicate that 8–13% of women of reproductive age have PCOS. Worldwide, up to 70% of afflicted women go undetected.

People are looking for ways to control their undesired hair growth as awareness of these conditions increases, which is driving up demand for topical androgen receptor inhibitors. The increasing prevalence of androgen-related conditions is a significant growth factor for the topical androgen receptor inhibitors market.


Topical Androgen Receptor Inhibitors Market overview
Get more information on this report: Request Free Sample PDF

Topical Androgen Receptor Inhibitors Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Aging Population: According to the WHO, one in six persons on the globe will be 60 years of age or older by 2030. The number of individuals in the world who are 60 years of age or older is expected to double (to 2.1 billion) by 2050. Hormonal imbalances, particularly variations in androgen levels, can be brought on by aging. AGA and hirsutism are two androgen-related disorders that are exacerbated by these abnormalities. Male-pattern baldness, also known as androgenetic alopecia, is a disorder that is frequently linked to aging. Hormonal changes, especially those related to androgen levels, can exacerbate hair loss in older people. Since topical androgen receptor inhibitors (TARIs) are intended to control androgen activity, they are relevant for treating conditions more common in the aging population. Therefore, the growing aging population is a substantial growth factor for the topical androgen receptor inhibitors market.
  • Rising Awareness and Adoption of Cosmetic Solutions: Concerns about appearance, particularly those about hair loss, are frequently more pressing as people age. Age-related concerns about appearance are becoming increasingly widely accepted, and older people are generally better aware of the cosmetic options that are accessible. The topical androgen receptor inhibitors market  is influenced by this acceptance and awareness.
  • Growing Healthcare Spending: According to the data provided by World Health Organization; Global health spending hit US$9 trillion in 2020. New topical androgen receptor inhibitor clinical studies can more easily be started when there is sufficient financing for healthcare. Obtaining regulatory permissions and carrying out clinical trials might come at a significant expense. These procedures are made possible by more healthcare spending, which enables pharmaceutical companies to launch more advanced and novel drugs. Spending on healthcare helps to increase topical androgen receptor inhibitors market access and distribution networks, among other aspects of infrastructure. This is essential to guarantee that patients and healthcare professionals have widespread access to topical androgen receptor inhibitors. Pharmaceutical items can be distributed and made accessible more efficiently with the support of a well-established healthcare infrastructure.

Challenges

  • High Cost of Topical Androgen Receptor Inhibitors: For some patient populations, the high cost of topical androgen receptor inhibitors may prevent them from being prescribed. Market penetration may be restricted as a result of a smaller group of people who can afford or are prepared to invest in these treatments due to affordability problems. The price of topical androgen receptor inhibitors may have an impact on patients' compliance with prescribed treatment plans. Patients may be less inclined to regularly take the medication as directed if they believe the treatment is too costly, which could have an adverse effect on overall market growth and result in unfavorable outcomes.
  • Limited Efficacy in Severe Cases may Hinder the Growth of the topical androgen receptor inhibitors market
  • Availability of Alternative Treatments may Hinder the Growth of the Market.

Topical Androgen Receptor Inhibitors Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~ 14%

Base Year Market Size (2023)

 ~ USD 40 Million

Forecast Year Market Size (2036)

 ~ USD 221.8 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Topical Androgen Receptor Inhibitors Segmentation

Indication (Androgenetic Alopecia, Hirsutism)

The Androgenetic alopecia segment in the topical androgen receptor inhibitors market is anticipated to hold a share of 55% during the forecast period. Several factors affect the growth of Topical Androgen Receptor Inhibitors (TARI) in the Androgenetic Alopecia (AGA) segment. People are looking for effective remedies, like TARI, as a result of growing awareness of AGA treatments that are available, as well as rising concerns about appearance and the desire to seem younger. Personalized medicine and patient-centered healthcare are popular trends that support the creation of individualized treatment plans. TARI fits in with this patient-centered strategy as a targeted treatment for AGA. Additionally, people now have localized, non-invasive therapy alternatives due to the development and marketing of topical formulations like Clascoterone that can block androgen receptors. The  market in the AGA segment is expanding as a result of all these elements.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

The hospital pharmacy segment in the topical androgen receptor inhibitors market is anticipated to hold a share of 47% by the end of 2036. Patients seeking topical androgen receptor inhibitors can benefit from the clinical experience and supervision of pharmacists and dermatologists, who are frequently available in hospital pharmacies. The availability of expert guidance boosts patients' trust in the efficiency and appropriate administration of these drugs. Prescription drugs frequently contain tartrogen receptor inhibitors. To guarantee that patients receive the recommended dosage and formulation, hospital pharmacies are essential in the distribution of prescription pharmaceuticals. Given these factors, it is projected that this segment's market will expand.

Our in-depth analysis of the global market includes the following segments:

          Indication

  • Androgenetic Alopecia
  • Hirsutism

          Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Topical Androgen Receptor Inhibitors Industry - Regional Synopsis

North American Market Forecast

Topical androgen receptor inhibitors market in North America is anticipated to hold the largest share of 34% during the forecast period. This is mostly because there aren't many resources available in the region and the demand for cosmetic operations is rising. The main cause was the rising use of aesthetic procedures in the region to improve the appearance of both adult and senior citizens. Male pattern baldness and unwanted hair growth are two cosmetic concerns that are driving up demand for solutions that address them since looks and aesthetics are becoming more and more important in society. It is therefore expected that the market in the North American region will expand.

APAC Market Statistics

Asia Pacific topical androgen receptor inhibitors market is poised to hold the second largest share of 22% during the forecast period. In the coming years, there will likely be significant growth in the Asia-Pacific region. This is a result of an increase in PCOS and hirsutism cases as well as cosmetic operations performed by more people to remove excessive body hair. In the Asia-Pacific, South Korea, China, Japan, and India are the largest markets. This is mostly due to the high diagnostic rates and widespread awareness of laser hair removal procedures in these nations. Another factor contributing to the growth of this market in the Asia-Pacific region is the fact that Japan has the highest number of laser hair removal operations performed worldwide. PCOS, or polycystic ovarian syndrome, is increasingly frequent in women and can cause hirsutism. This is the primary factor propelling the topical androgen receptor inhibitors market in this region.

Research Nester
Topical Androgen Receptor Inhibitors Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Topical Androgen Receptor Inhibitors Market

top-features-companies
    • Cosmo Pharmaceuticals
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Suzhou Kintor Pharmaceuticals Inc
    • Sun Pharmaceutical Industries Limited
    • Aranda Pharma Ltd
    • Selleck Chemicals

In-the-news

In The News

  • Aug 2020- The U.S. FDA has approved the first-in-class androgen receptor inhibitor, carotene cream 1% (Winlevi, Cassiopea), for the treatment of acne vulgaris in individuals 12 years of age and older.
  • Apr 2021- The National Medical Products Administration has given the green light for Kintor Pharmaceutical, a clinical-stage biotechnology company developing novel small molecule and biological therapeutics, to start GT20029 (gel/tincture) clinical trials for the treatment of androgenetic alopecia and acne.
  • Nov 2023- The supplemental new drug application for XTANDI® has been approved by the U.S. Food and Drug Administration (FDA), as announced by Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. With this approval, XTANDI turns out the first and only androgen receptor signaling inhibitor authorized by the FDA for the management of patients with biochemically driven recurrence of nonmetastatic castration-sensitive prostate cancer (nmCSPC) who are at high risk of developing metastatic disease.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5828
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

A rising aging population, growing healthcare spending and rising acceptance of cosmetic procedures are the major factors driving the growth of the topical androgen receptor inhibitors market.

The market size of topical androgen receptor inhibitors is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2024 - 2036.

The major players in the market are Cosmo Pharmaceuticals, Suzhou Kintor Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Aranda Pharma Ltd, Selleck Chemicals, Astellas Pharma, Takeda Pharmaceutical, and Daiichi Sankyo.

The Androgenetic Alopecia segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Topical Androgen Receptor Inhibitors Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying